002581 Shandong Sinobioway Biomedicine
- 10.16
- -0.04-0.39%
Shandong Sinobioway Biomedicine News
Unnamed Pharmaceutical (002581.SZ) withdraws from Qianhai Weiming M&A Fund
Unnamed Pharmaceutical (002581.SZ) issued an announcement, and the company held the 5th term of directors on May 30, 2024...
Unnamed Pharmaceutical (002581.SZ) received a dividend of 215 million yuan from the participating company Beijing Kexing
Unnamed Pharmaceutical (002581.SZ) announced that the company received a dividend of 215 million yuan from the participating company Beijing Kexing Biological Products Co., Ltd. (“Beijing Kexing” for short).
Unnamed Pharmaceutical (002581.SZ): Net loss of 27.704 million yuan in the first quarter
On April 30, Ge Longhui Pharmaceutical (002581.SZ) released its report for the first quarter of 2024, achieving operating income of 83.8048 million yuan, an increase of 10.85% over the previous year; net profit attributable to shareholders of listed companies - 27.704 million yuan, net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 28.33 million yuan, and basic earnings per share - 0.042 yuan.
Unnamed Pharmaceutical (002581.SZ) reported first-quarter results with a net loss of 27.7041 million yuan
According to Zhitong Finance App, Unnamed Pharmaceutical (002581.SZ) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 83.8048 million yuan, an increase of 10.85% over the previous year; net loss attributable to shareholders of listed companies was 27.7041 million yuan; net loss attributable to shareholders of listed companies deducted 28.33 million yuan for non-recurring profit and loss; basic loss per share was 0.0420 yuan/share.
Express News | Unnamed Medicine Receives Letter of Concern: Failure to disclose related parties and non-operating related transactions in accordance with regulations
The A-share CRO concept changed and increased, with Punitest rising by nearly 5%, while Tailong Pharmaceutical, Hongbo Pharmaceutical, Haite Biotech, and Blue Biotech followed suit
The A-share CRO concept changed and increased, with Punitest rising by nearly 5%, while Tailong Pharmaceutical, Hongbo Pharmaceutical, Haite Biotech, and Blue Biotech followed suit
The biological products sector fluctuated higher, and Ganli Pharmaceutical rose or stopped
Gelonghui, April 1 | Ganli Pharmaceutical had previously risen and stopped. Unnamed Pharmaceuticals rose more than 9%, while Changchun Hi-Tech, Tonghua Dongbao, and Anke Biotech rose.
Unnamed Pharmaceuticals (002581.SZ): Shareholder Gao Baolin and his co-actors have not reduced their holdings at the end of the reduction period
Gelonghui, March 4 | Unnamed Pharmaceutical (002581.SZ) announced that the company recently received a “Notice Letter on the Expiration of the Share Reduction Period” issued by shareholder Mr. Gao Baolin and his co-actor Mr. Wang Mingxian. As of the announcement date, the period of this holdings reduction plan had expired, and the company's shareholder Mr. Gao Baolin and his co-actor, Mr. Wang Mingxian, had not reduced their holdings in the company.
Unnamed Pharmaceutical (002581.SZ): Received 53.82 million yuan in dividends from participating companies
Gelonghui, Feb. 5 | Weiming Pharmaceutical (002581.SZ) announced that recently, Shandong Weiming Biomedical Co., Ltd. received a dividend of RMB 53.82 million from the participating company Beijing Kexing Biological Products Co., Ltd. (“Beijing Kexing”).
Unnamed Pharmaceutical (002581.SZ): Expected net loss of 240 million yuan to 345 million yuan in 2023
On January 30, Gelonghui Pharmaceutical (002581.SZ) announced that it expects a net loss of 243.39 million yuan to 345.09 million yuan in 2023, after deducting non-net loss of 228.87 million yuan to 330.57 million yuan. According to corporate accounting standards and relevant accounting policy regulations, some long-term assets of the company were tested for impairment based on comprehensive influencing factors such as the company's actual operating conditions, changes in the industry market, and asset operation. The initial judgment was that there may be signs of impairment. According to the company's preliminary estimates, the company is expected to calculate impairment provisions for relevant long-term assets in the 2023 annual report: reduction in fixed assets
Unknown Pharmaceutical (002581.SZ): Tianjin's unfamous interferon α2b spray plans to win the bid collection project
Unnamed Pharmaceutical (002581.SZ) issued an announcement. Recently, Tianjin Weiming Biomedical Co., Ltd., a holding subsidiary of the company...
Sinobioway Biomedicine's Unit to Relocate
Shandong Sinobioway Biomedicine's (SHE:002581) unit, Peking University Weiming (Hefei) Biopharmaceutical, suspended operations as part of relocation plans. The pharmaceutical company will be relocated
Unnamed Pharmaceutical (002581.SZ), a wholly-owned subsidiary of Unnamed Pharmaceutical (002581.SZ), ceased production in Hefei and relocated
Unnamed Pharmaceutical (002581.SZ) announced that Peking University Weiming (Hefei) Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company...
Unknown drug: A case was filed by the Securities Regulatory Commission on suspicion of illegal disclosure
Gelonghui November 23 | Unknown Pharmaceutical Notice. The company received the “Notice of Case Filing” issued by the China Securities Regulatory Commission on November 21. The China Securities Regulatory Commission decided to file a case against the company because the disclosure of the company's information was suspected of being illegal and illegal. Currently, the company's business conditions are normal.
[Instant Analysis of BT Financial Report] Unnamed Pharmaceutical's 2023 Interim Report: Operating Revenue Increased by 11.47%, Net Profit Loss Expanded, and Cash Flow Pressure Revealed
The 2023 interim report of Unnamed Pharmaceutical (stock code: 002581) has been announced. In the reporting period, the revenue of Unnamed Pharmaceutical was 209,166,285.01 yuan, an increase of 11.47% compared to 187,644,945.23 yuan in the same period last year. However, net profit attributable to shareholders of listed companies during the reporting period was -53,757,277.48 yuan, a decrease of 324.39% compared to 23,956,571.47 yuan in the same period last year. At the same time, net profit attributable to shareholders of listed companies during the reporting period after deducting non-recurring profit and loss was -48,1
Unnamed Medicine (002581.SZ): Received 5 million yuan in government incentives
Gelonghui, September 1: Unnamed Pharmaceutical (002581.SZ) announced that according to the “Notice of the Xiamen Municipal People's Government on Certain Measures to Accelerate the High-Quality Development of the Biomedical Industry” (Xiamen Regulation (2020) No. 7), Unnamed Biomedical Co., Ltd. (“Xiamen Weiming”), a wholly-owned subsidiary of Shandong Weiming Biomedical Co., Ltd. (“Xiamen Weiming”), received a total of RMB 5 million in government incentives related to revenue on August 30, 2023, accounting for 34.04% of the company's most recent audited net profit attributable to shareholders of listed companies.
Sinobioway Biomedicine Taps Builders for Planned Industrial Park
Shandong Sinobioway Biomedicine (SHE:002581) tapped Shandong Qiying Industry Investment Development and Shandong Jutai Industry Development to construct its planned industrial park in Zhangdian Econom
The biomedical sector shook and fell; Kangchen Pharmaceutical fell more than 7%
GLONGHUI August 2: Kangchen Pharmaceutical fell more than 7%, followed by unknown pharmaceuticals, Rongchang Biology, Gan Li Pharmaceutical, Sansheng Guojian, and Yifang Biotech.
Changes in A-shares 丨Failure to comply with the review procedures in accordance with regulations and failure to disclose important matters in a timely manner Unnamed Pharmaceutical's supervision letter from the Shenzhen Stock Exchange
GLONGHUI July 19丨Unknown Pharmaceuticals (002581.SZ) received a regulatory letter from the Shenzhen Stock Exchange today. According to the regulatory letter, the company failed to comply with the review process in accordance with regulations and failed to disclose important matters in a timely manner. In May 2022, Hangzhou Qiangxin signed an agreement with Xiamen Weiming, a subsidiary of the company, and others, agreeing that Hangzhou Qiangxin would subscribe to Xiamen Unnamed 67.6749 million yuan in additional registered capital at a premium and obtain about 34% of the shares in Xiamen Weiming. The company failed to carry out the review procedure in accordance with the company's articles of association. Xiamen Weiming completed industrial and commercial changes on May 18, 2022, and the shareholding structure underwent major changes. The company did not disclose it in a timely manner
Unknown Pharmaceuticals (002581.SZ): Advance loss of 47.649 million yuan in the first half of the year, year-on-year profit and loss
On July 14, 丨Unknown Pharmaceuticals (002581.SZ) announced its 2023 semi-annual results forecast. Net profit and loss attributable to shareholders of listed companies during the reporting period was 476.49 million yuan, a year-on-year profit to loss; net profit loss of 42.0339 million yuan after deducting non-recurring profit and loss; and a basic loss of 0.0722 yuan/share in earnings per share. The reason for the decline in the company's performance during the reporting period was a decrease in the company's investment income.
Analysis
Price Target
No Data
